Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer

References

• zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? Lancet2(8312), 1370–1372 (1982).
   PubMed Web of Science ®Google Scholar
• zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. Bibl. Haematol.43, 569–571 (1975).
   Google Scholar
• IARC. Human papilloma viruses. IARC Monogr. Eval. Carcinog. Risks Hum.64 (1995).
   PubMedGoogle Scholar
• IARC. Handbooks of cancer prevention. IARC 10 (2005).
   Google Scholar
• Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology324(1), 17–27 (2004).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase5(2.0), IARC Press, Lyon, France (2004).
   Google Scholar
• Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111(2), 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88(1), 63–73 (2003).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev.14(5), 1157–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet366(9490), 991–998 (2005).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer89(1), 101–105 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas KK, Hughes JP, Kuypers JM et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J. Infect. Dis.182(4), 1097–1102 (2000).
   PubMed Web of Science ®Google Scholar
• Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex. Transm. Dis.30(7), 581–587 (2003).
   PubMedGoogle Scholar
• Moscicki AB. Impact of HPV infection in adolescent populations. J. Adolesc. Health37(6 Suppl.), S3–S9 (2005).
   PubMed Web of Science ®Google Scholar
• Collins S, Mazloomzadeh S, Winter H et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG109(1), 96–98 (2002).
   PubMed Web of Science ®Google Scholar
• Munoz N, Mendez F, Posso H et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis.190(12), 2077–2087 (2004).
   PubMed Web of Science ®Google Scholar
• Sellors JW, Karwalajtys TL, Kaczorowski J et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ168(4), 421–425 (2003).
   PubMed Web of Science ®Google Scholar
• Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis.191(11), 1808–1816 (2005).
   PubMed Web of Science ®Google Scholar
• Herrero R, Hildesheim A, Bratti C et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J. Natl Cancer Inst.92(6), 464–474 (2000).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer106(6), 896–904 (2003).
   PubMed Web of Science ®Google Scholar
• Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol.92(4 Pt 2), 727–735 (1998).
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Platt RW, Duarte-Franco E et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl Cancer Inst.95(17), 1336–1343 (2003).
   PubMedGoogle Scholar
• Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch. Pathol. Lab. Med.127(8), 930–934 (2003).
   PubMed Web of Science ®Google Scholar
• Trottier H, Mahmud S, Lindsay L, Jenkins D, Wieting S, Franco E. Natural history of HPV infection and cervical lesions in women from the placebo arm of an AS04 adjuvanted HPV-16/18 L1 vaccine trial. EUROGIN2006.
   Google Scholar
• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol.32(Suppl. 1), S16–S24 (2005).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER – Cancer Statistics Review, 1973–1998. MD, USA, 2001.
   Google Scholar
• Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ164(8), 1151–1152 (2001).
   PubMed Web of Science ®Google Scholar
• Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol. Oncol.78(2), 97–105 (2000).
   PubMed Web of Science ®Google Scholar
• Andersson S, Larson B, Hjerpe A et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet. Gynecol. Scand.82(10), 960–965 (2003).
   PubMedGoogle Scholar
• Harper DM. Why am I scared of HPV? CA Cancer J. Clin.54(5), 245–247 (2004).
   PubMed Web of Science ®Google Scholar
• Naumann RW, Crispens MA, Alvarez RD, Partridge EE, Shingleton HM, Kilgore LC. Treatment of cervical dysplasia with large loop excision of the transformation zone: is endocervical curettage necessary? South. Med. J.89(10), 961–965 (1996).
   PubMedGoogle Scholar
• ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening. Obstet. Gynecol.102(2), 417–427 (2003).
   PubMedGoogle Scholar
• Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin.52(6), 342–362 (2002).
   PubMed Web of Science ®Google Scholar
• Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and scientific justification: third version (2003). Ann. Oncol.14(7), 973–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA287(16), 2120–2129 (2002).
   PubMed Web of Science ®Google Scholar
• National Health Services. Making a difference – NHS cervical screening programme. Annual review 2004. NHS, UK, 2004.
   Google Scholar
• Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J. Natl Cancer Inst.98(2), 82–83 (2006).
   PubMedGoogle Scholar
• Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol. Oncol.99(3 Suppl. 1), S7–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sasieni P. Natural history of cervical human papillomavirus. Lancet358(9292), 1550–1551 (2001).
   PubMedGoogle Scholar
• Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet362(9399), 1871–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sasieni P, Davies P et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br. J. Cancer83(5), 561–565 (2000).
   PubMedGoogle Scholar
• Castle PE, Lorincz AT, Mielzynska-Lohnas I et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J. Clin. Microbiol.40(3), 1088–1090 (2002).
   PubMedGoogle Scholar
• Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl Cancer Inst.93(4), 293–299 (2001).
   PubMed Web of Science ®Google Scholar
• van Doorn LJ, Quint W, Kleter B et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J. Clin. Microbiol.40(3), 979–983 (2002).
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol.4(2), 122–126 (1997).
   PubMedGoogle Scholar
• Christensen ND, Hopfl R, DiAngelo SL et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J. Gen. Virol.75(Pt 9), 2271–2276 (1994).
   PubMed Web of Science ®Google Scholar
• Hagensee ME, Olson NH, Baker TS, Galloway DA. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J. Virol.68(7), 4503–4505 (1994).
   PubMed Web of Science ®Google Scholar
• Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J. Gen. Virol.75(Pt 8), 2075–2079 (1994).
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol.69(6), 3959–3963 (1995).
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA92(25), 11553–11557 (1995).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Chandrachud LM, O’Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology219(1), 37–44 (1996).
   PubMed Web of Science ®Google Scholar
• Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int.68(5), 2298–2303 (2005).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Adab P. The immunology of vaccination. In: Vaccines. 4th Edition. Plotkin SA, Orenstein WA, Offit PA (Eds). PA, USA, 31–45 (2004).
   Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol.2(8), 675–680 (2001).
   PubMed Web of Science ®Google Scholar
• Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol.165(10), 5780–5787 (2000).
   PubMed Web of Science ®Google Scholar
• Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J. Immunol.165(2), 618–622 (2000).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature388(6640), 394–397 (1997).
   PubMed Web of Science ®Google Scholar
• Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol.17, 593–623 (1999).
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science285(5428), 732–736 (1999).
   PubMed Web of Science ®Google Scholar
• Kaiser P, Rothwell L, Galyov EE, Barrow PA, Burnside J, Wigley P. Differential cytokine expression in avian cells in response to invasion by Salmonella typhimurium, Salmonella enteritidis and Salmonella gallinarum. Microbiology146(Pt 12), 3217–3226 (2000).
   PubMed Web of Science ®Google Scholar
• Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol.2(10), 947–950 (2001).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine18(22), 2416–2425 (2000).
   PubMed Web of Science ®Google Scholar
• De Becker G, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol.12(6), 807–815 (2000).
   PubMed Web of Science ®Google Scholar
• Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines2(2), 219–229 (2003).
   PubMedGoogle Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol.6, 495–524 (1995).
   PubMedGoogle Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Schwarz TF. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old. J. Clin. Oncol.24(18S), 1008 (2006).
   Google Scholar
• Dubin G. Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus-like particle (VLP) vaccine with novel AS04 adjuvant in pre-teens/adolescents. ICAAC2005.
   Google Scholar
• Rombo L, Dubin G. AS04 adjuvanted human papillomavirus (HPV) 16/18 L1 virus-like particle (VLP) vaccine for the prevention of cervical cancer is well-tolerated and immunogenic in 10-to-14-year-old adolescent girls. ESPID2006.
   Google Scholar
• CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rpt55(RR-15), 1–48 (2006).
   PubMedGoogle Scholar
• Frazer IH, Cox JT, Mayeaux EJ Jr et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr. Infect. Dis. J.25(2 Suppl.), S65–S81 (2006).
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis.10(11), 1915–1923 (2004).
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, Patrick DM, Schulzer M et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex. Transm. Infect.81(3), 207–212 (2005).
   PubMedGoogle Scholar
• Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J. Clin. Virol.32(Suppl. 1), S34–S42 (2005).
   Google Scholar
• Rohan TE, Burk RD, Franco EL. Toward a reduction of the global burden of cervical cancer. Am. J. Obstet. Gynecol.189(4 Suppl.), S37–S39 (2003).
   PubMedGoogle Scholar
• Bosch FX. The aetiology of cervical cancer. NHSCSP22 (2005).
   Google Scholar
• Laimins LA. The biology of human papillomaviruses: from warts to cancer. Infect. Agents Dis.2(2), 74–86 (1993).
   PubMedGoogle Scholar
• Genther SM, Sterling S, Duensing S, Munger K, Sattler C, Lambert PF. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol.77(5), 2832–2842 (2003).
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Yoshikawa H, Yasugi T et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J. Med. Virol.62(2), 251–258 (2000).
   PubMed Web of Science ®Google Scholar